The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.

Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.

APRNs developed a discharge program which reduced readmission rates for patients receiving immunotherapy for advanced melanoma.

Holistic options like acupuncture and music therapy may benefit those undergoing cancer treatment.

Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.

Neoadjuvant cemiplimab elicited promising pathologic complete responses in patients with cutaneous squamous cell carcinoma.

A quality-of-life analysis of the pivotal Destiny-Breast04 trial showed that trastuzumab deruxtecan outperformed physician’s choice of treatment in delaying definitive deterioration.

In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.

Because immune-related adverse events can be hard to diagnose, patient education and clear avenues of communication with an oncology care team are critical, according to investigators at the 2022 Pan Pacific Lymphoma Conference.

In this episode of The Vitals, Donna Herrera Bell, MSN, APRN, FNP-C, highlights how nurses can eliminate barriers to fertility discussions among adolescent and young adult patients with cancer.

Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.

Conversations surrounding fertility preservation may differ between young men and women with cancer, according to Donna Herrera Bell, MSN, APRN, FNP-C.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.

Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.

Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.

Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.

LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.

An expert from The University of Texas MD Anderson Cancer Center offers advice on the best diet to enrich a patient’s microbiome and consequent immunotherapy response.

Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.

An expert from The University of Texas MD Anderson Cancer Center highlights findings demonstrating the impact that diet and probiotics have in immunotherapy responses.

New data support increased fiber consumption and decreased probiotic use among patients receiving immunotherapy.

A novel regimen of relatlimab, an LAG-3 inhibitor, plus nivolumab doubled progression-free survival in patients with untreated, advanced melanoma.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses findings indicating that patients with agitated delirium may be under-sedated, in accordance with their personalized sedation goal.

An expert discusses the value of enrolling patients with soft tissue sarcoma in histologically specific clinical trials.